Pembrolizumab en cáncer de mama triple negativo en etapa temprana o localmente avanzado (neoadyuvancia/ adyuvancia) / Pembrolizumabe no câncer de mama triplo negativo em estágio inicial ou localmente avançado (neoadjuvante/adjuvante)
Buenos Aires; IECS; mayo 2023.
Non-conventional
in Es
| BRISA
| ID: biblio-1518680
Responsible library:
BR1.1
Subject(s)
Full text:
1
Collection:
05-specialized
Database:
BRISA
Main subject:
Triple Negative Breast Neoplasms
/
Antibodies, Monoclonal
Type of study:
Health_technology_assessment
Limits:
Humans
Language:
Es
Year:
2023
Document type:
Non-conventional
Country of publication:
Argentina